Yong Han

Yong Han

Auto-generated profile, based on publicly available information

Yong Han

Clinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
XZXiqun Zhu
Xiqun Zhu
YHYong Han
Yong Han
JDJing Du
Jing Du
RLRenzhong Liu
Renzhong Liu
KJKetao Jin
Ketao Jin
WYWei Yi
Wei Yi
Microbiota-gut-brain axis and the central nervous system Microbiota-gut-brain axis and the central nervous system

12 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TGTian Gao
Tian Gao
YHYong Han
Yong Han
LYLing Yu
Ling Yu
SASheng Ao
Sheng Ao
ZLZiyu Li
Ziyu Li
JJJiafu Ji
Jiafu Ji
Identification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNA2 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNA2 was closely associated with tamoxifen resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, though CCNA2-Drug interaction network, we demonstrated the interactions between CCNA2 and several available cancer drugs. Overall, we suggest that CCNA2 is a biomarker for the prognosis of ER+ breast cancer and monitoring of tamoxifen efficacy. It's also a promising target for developing new strategies to prevent or even reverse tamoxifen resistance. Moreover, CCNA2 expression may help monitoring tamoxifen efficacy and directing personalized therapies. Nevertheless, in vivo and in vitro experiments and multi-center randomized controlled clinical trials are still needed before its application in clinical settings.

5 February 2016 in Scientific Reports
Verified
Journal Article
Open access
DHDongsheng Huang
Dongsheng Huang
HDHongying Duan
Hongying Duan
HHHao Huang
Hao Huang
XTXiangmin Tong
Xiangmin Tong
YHYong Han
Yong Han
ZZZhongsheng Zhao
Zhongsheng Zhao
Cisplatin remains to be primary chemotherapeutic drug for gastric cancer patients, especially for advanced stage ones. However, primary or acquired resistance often occurs with the mechanisms being not well understood, which results in relapse of the cancer and poor survival. Herein, we found that HER2 upregulation was associated with cisplatin resistance. We observed that cisplatin-resistant gastric cancer cells underwent a morphological change similar to epithelial-mesenchymal transition (EMT) which is mediated by HER2 overexpression. When specific monoclonal antibody Herceptin, small molecular targeted drug CP724714, or small interfering RNA against HER2 was applied, the EMT-like phenotypic change was dramatically reversed. More importantly, the IC50 and Resistance Index of resistant gastric cancer cells to cisplatin were also decreased by any of these treatments.We demonstrated that expression and amplification of HER2 positively correlated with expression of EMT-related transcription factor Snail in gastric cancer tissues. Furthermore, for the first time, we found that HER2/Snail double positive gastric cancer patients had poorer survival than single positive or double negative counterparts, which provided experimental evidence for the necessity of HER2/Snail double testing in gastric cancer. In conclusion, this study provides some clues of the association of cisplatin resistance with HER2 upregulation-induced EMT in gastric cancer cells.

9 October 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
HHHao Huang
Hao Huang
YHYong Han
Yong Han
CZCheng Zhang
Cheng Zhang
JWJian Wu
Jian Wu
JFJunnan Feng
Junnan Feng
CSChengchao Shou
Chengchao Shou

14 October 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
HDHongying Duan
Hongying Duan
LCLing Chen
Ling Chen
LQLike Qu
Like Qu
HYHua Yang
Hua Yang
SSSonya Wei Song
Sonya Wei Song
CSChengchao Shou
Chengchao Shou
Chronic infection of Mycoplasma hyorhinis (M. hyorhinis) has been postulated to be associated with several types of cancer, but its effect on patients' survival and host factors mediating its infection remain unclear. Herein, we demonstrated that M. hyorhinis p37 protein expression in gastric cancer tissues predicts poor survival and associates with metastasis. M. hyorhinis infects mammalian cells and promotes gastric cancer cell invasiveness via its membrane protein p37. Synthesized peptide corresponding to the N-terminus of p37 prevents M. hyorhinis infection. Host Annexin A2 (ANXA2) interacts with the N-terminus of p37. In addition, EGFR forms a complex with p37 and ANXA2, and is required for M. hyorhinis–induced phosphorylation and membrane recruitment of ANXA2. M. hyorhinis infection is inhibited by siRNA-mediated knockdown of ANXA2 or EGFR, but is enhanced by expression of ectopic ANXA2 or EGFR. Downstream of ANXA2 and EGFR, the NF-κB pathway is activated and mediates M. hyorhinis–driven cell migration. In conclusion, our study unveils the effect of M. hyorhinis infection on gastric cancer survival and uncovers the mechanisms by which M. hyorhinis infects mammalian cells and promotes cancer cell migration. Cancer Res; 74(20); 5782–94. ©2014 AACR.

1 December 2018 in Stem Cell Reports
Verified
Journal Article
Open access
DJDengbo Ji
Dengbo Ji
TZTiancheng Zhan
Tiancheng Zhan
MLMing Li
Ming Li
YYYunfeng Yao
Yunfeng Yao
JJJinying Jia
Jinying Jia
JGJin Gu
Jin Gu
Chemo-/radiotherapy resistance is the main cause accounting for most treatment failure in colorectal cancer (CRC). Tumor-initiating cells (TICs) are the culprit leading to CRC chemo-/radiotherapy resistance. The underlying regulation mechanism of TICs in CRC remains unclear. Here we discovered that miR-15b expression positively correlated with therapeutic outcome in CRC. Expression of miR-15b in pretreatment biopsy tissue samples predicted tumor regression grade (TRG) in rectal cancer patients after receiving neoadjuvant radiotherapy (nRT). Expression of miR-15b in post-nRT tissue samples was associated with therapeutic outcome. DCLK1 was identified as the direct target gene for miR-15b and its suppression was associated with self-renewal and tumorigenic properties of DCLK1+ TICs. We identified B lymphoma Mo-MLV insertion region l homolog (BMI1) as a downstream target regulated by miR-15b/DCLK1 signaling. Thus, miR-15b may serve as a valuable marker for prognosis and therapeutic outcome prediction. DCLK1 could be a potential therapeutic target to overcome chemo-/radioresistance in CRC.